The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy

A randomized controlled study

Maria B. Grant, Robert N. Mames, Constance Fitzgerald, Kaushik M. Hazariwala, Rhonda Cooper-Dehoff, Sergio Caballero, Kerry S. Estes

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

OBJECTIVE - The pilot study examined the ability of octreotide to retard progression of diabetic retinopathy (DR) and delay the need for panretinal photocoagulation (PRP) in patients with advanced stages of retinal disease. RESEARCH DESIGN AND METHODS - Patients with severe nonproliferative DR (NPDR) or early non-high-risk proliferative DR (PDR) were randomly assigned to conventional diabetes management (control group, 12 patients) or to treatment with maximally tolerated doses of octreotide (200-5,000 μg/day subcutaneously; 11 patients). Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high- risk PDR requiring laser surgery. Endocrine assessments occurred at 3-month intervals during the study. RESULTS - Only 1 of 22 eyes from patients treated with octreotide reached high-risk PDR requiring PRP, compared with control patients, in whom 9 of 24 eyes required PRP. The decreased incidence of progression requiring laser surgery was statistically significant if events were considered independently (P <0.006). The incidence of ocular disease progression was only 27% in patients treated with octreotide compared with 42% in patients with conventional diabetes management. This treatment effect on whether the retina worsened approached statistical significance using repeated measures analysis (P = 0.0605). Endocrine management was similar between treatment groups. Thyroxine replacement therapy was administered to maintain a euthyroid state for all octreotide-treated patients and 7 of 12 control patients. CONCLUSIONS - Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery.

Original languageEnglish (US)
Pages (from-to)504-509
Number of pages6
JournalDiabetes Care
Volume23
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Octreotide
Diabetic Retinopathy
Light Coagulation
Laser Therapy
Therapeutics
Retinal Diseases
Maximum Tolerated Dose
Eye Diseases
Incidence
Thyroxine
Disease Progression
Retina
Research Design

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Grant, M. B., Mames, R. N., Fitzgerald, C., Hazariwala, K. M., Cooper-Dehoff, R., Caballero, S., & Estes, K. S. (2000). The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study. Diabetes Care, 23(4), 504-509.

The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy : A randomized controlled study. / Grant, Maria B.; Mames, Robert N.; Fitzgerald, Constance; Hazariwala, Kaushik M.; Cooper-Dehoff, Rhonda; Caballero, Sergio; Estes, Kerry S.

In: Diabetes Care, Vol. 23, No. 4, 2000, p. 504-509.

Research output: Contribution to journalArticle

Grant, MB, Mames, RN, Fitzgerald, C, Hazariwala, KM, Cooper-Dehoff, R, Caballero, S & Estes, KS 2000, 'The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study', Diabetes Care, vol. 23, no. 4, pp. 504-509.
Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-Dehoff R, Caballero S et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study. Diabetes Care. 2000;23(4):504-509.
Grant, Maria B. ; Mames, Robert N. ; Fitzgerald, Constance ; Hazariwala, Kaushik M. ; Cooper-Dehoff, Rhonda ; Caballero, Sergio ; Estes, Kerry S. / The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy : A randomized controlled study. In: Diabetes Care. 2000 ; Vol. 23, No. 4. pp. 504-509.
@article{77974f19262f48e482b31f25c7770d6a,
title = "The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study",
abstract = "OBJECTIVE - The pilot study examined the ability of octreotide to retard progression of diabetic retinopathy (DR) and delay the need for panretinal photocoagulation (PRP) in patients with advanced stages of retinal disease. RESEARCH DESIGN AND METHODS - Patients with severe nonproliferative DR (NPDR) or early non-high-risk proliferative DR (PDR) were randomly assigned to conventional diabetes management (control group, 12 patients) or to treatment with maximally tolerated doses of octreotide (200-5,000 μg/day subcutaneously; 11 patients). Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high- risk PDR requiring laser surgery. Endocrine assessments occurred at 3-month intervals during the study. RESULTS - Only 1 of 22 eyes from patients treated with octreotide reached high-risk PDR requiring PRP, compared with control patients, in whom 9 of 24 eyes required PRP. The decreased incidence of progression requiring laser surgery was statistically significant if events were considered independently (P <0.006). The incidence of ocular disease progression was only 27{\%} in patients treated with octreotide compared with 42{\%} in patients with conventional diabetes management. This treatment effect on whether the retina worsened approached statistical significance using repeated measures analysis (P = 0.0605). Endocrine management was similar between treatment groups. Thyroxine replacement therapy was administered to maintain a euthyroid state for all octreotide-treated patients and 7 of 12 control patients. CONCLUSIONS - Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery.",
author = "Grant, {Maria B.} and Mames, {Robert N.} and Constance Fitzgerald and Hazariwala, {Kaushik M.} and Rhonda Cooper-Dehoff and Sergio Caballero and Estes, {Kerry S.}",
year = "2000",
language = "English (US)",
volume = "23",
pages = "504--509",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy

T2 - A randomized controlled study

AU - Grant, Maria B.

AU - Mames, Robert N.

AU - Fitzgerald, Constance

AU - Hazariwala, Kaushik M.

AU - Cooper-Dehoff, Rhonda

AU - Caballero, Sergio

AU - Estes, Kerry S.

PY - 2000

Y1 - 2000

N2 - OBJECTIVE - The pilot study examined the ability of octreotide to retard progression of diabetic retinopathy (DR) and delay the need for panretinal photocoagulation (PRP) in patients with advanced stages of retinal disease. RESEARCH DESIGN AND METHODS - Patients with severe nonproliferative DR (NPDR) or early non-high-risk proliferative DR (PDR) were randomly assigned to conventional diabetes management (control group, 12 patients) or to treatment with maximally tolerated doses of octreotide (200-5,000 μg/day subcutaneously; 11 patients). Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high- risk PDR requiring laser surgery. Endocrine assessments occurred at 3-month intervals during the study. RESULTS - Only 1 of 22 eyes from patients treated with octreotide reached high-risk PDR requiring PRP, compared with control patients, in whom 9 of 24 eyes required PRP. The decreased incidence of progression requiring laser surgery was statistically significant if events were considered independently (P <0.006). The incidence of ocular disease progression was only 27% in patients treated with octreotide compared with 42% in patients with conventional diabetes management. This treatment effect on whether the retina worsened approached statistical significance using repeated measures analysis (P = 0.0605). Endocrine management was similar between treatment groups. Thyroxine replacement therapy was administered to maintain a euthyroid state for all octreotide-treated patients and 7 of 12 control patients. CONCLUSIONS - Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery.

AB - OBJECTIVE - The pilot study examined the ability of octreotide to retard progression of diabetic retinopathy (DR) and delay the need for panretinal photocoagulation (PRP) in patients with advanced stages of retinal disease. RESEARCH DESIGN AND METHODS - Patients with severe nonproliferative DR (NPDR) or early non-high-risk proliferative DR (PDR) were randomly assigned to conventional diabetes management (control group, 12 patients) or to treatment with maximally tolerated doses of octreotide (200-5,000 μg/day subcutaneously; 11 patients). Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high- risk PDR requiring laser surgery. Endocrine assessments occurred at 3-month intervals during the study. RESULTS - Only 1 of 22 eyes from patients treated with octreotide reached high-risk PDR requiring PRP, compared with control patients, in whom 9 of 24 eyes required PRP. The decreased incidence of progression requiring laser surgery was statistically significant if events were considered independently (P <0.006). The incidence of ocular disease progression was only 27% in patients treated with octreotide compared with 42% in patients with conventional diabetes management. This treatment effect on whether the retina worsened approached statistical significance using repeated measures analysis (P = 0.0605). Endocrine management was similar between treatment groups. Thyroxine replacement therapy was administered to maintain a euthyroid state for all octreotide-treated patients and 7 of 12 control patients. CONCLUSIONS - Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery.

UR - http://www.scopus.com/inward/record.url?scp=0034082810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034082810&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 504

EP - 509

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -